skip to main content

Initial PAH Dual Combination Therapy — EECC MCQ

Instant feedback + full explanation. One question, done properly.

ModeratePulmonary Vascular DiseaseInitial PAH Dual Combination TherapyEECC

A 60-year-old man with newly diagnosed PAH is risk-stratified using the ESC/ERS 2022 risk assessment approach. He has WHO FC II, 6MWD 480 m, NT-proBNP 200 pg/mL, cardiac index 3.0 L/min/m², and RA pressure 5 mmHg. All parameters indicate low risk. What initial treatment is recommended?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: E — Initial dual oral combination therapy (ERA + PDE5 inhibitor) is recommended for treatment-naïve PAH patients at low-intermediate risk — the AMBITION trial showed upfront combination therapy was superior to monotherapy

The 2022 ESC/ERS PH Guidelines recommend upfront dual oral combination therapy for most newly diagnosed PAH patients at low-intermediate risk, based on the AMBITION trial (2015): initial combination of ambrisentan (ERA) + tadalafil (PDE5i) reduced the risk of clinical failure by 50% compared with monotherapy (either agent alone). Treatment algorithm: (1) Low-intermediate risk: initial dual oral therapy (ERA + PDE5i); (2) High risk at diagnosis: initial triple therapy including IV/SC prostacyclin (ERA + PDE5i + IV epoprostenol or SC treprostinil); (3) Vasoreactive (positive acute vasodilator testing — ~10% of IPAH): high-dose CCB trial first. (4) Reassess at 3-6 months and escalate if not meeting low-risk targets. The only scenario where monotherapy may be appropriate is positive vasoreactivity with CCB response or specific contraindications to combination components.

Reference: ESC/ERS (2022): PH Guidelines; AMBITION Trial